Market Overview

Bank of America Downgrades Nektar Therapeutics to Underperform

Bank of America has downgraded Nektar Therapeutics (NASDAQ: NKTR) from Neutral to Underperform and maintains its $6 price objective.

Posted-In: Bank of AmericaDowngrades Price Target Pre-Market Outlook Analyst Ratings

 

Related Articles (NKTR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters